{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+A+%28IgA%29+Nephropathy&page=2",
    "query": {
      "condition": "Immunoglobulin A (IgA) Nephropathy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+A+%28IgA%29+Nephropathy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T13:49:37.909Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03366337",
      "title": "A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy",
        "CKD Associated With Type 1 Diabetes",
        "Focal Segmental Glomerulosclerosis",
        "Autosomal Dominant Polycystic Kidney"
      ],
      "interventions": [
        {
          "name": "Bardoxolone methyl capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 103,
      "start_date": "2017-12-26",
      "completion_date": "2019-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03366337"
    },
    {
      "nct_id": "NCT07054684",
      "title": "Study of BHV-1400 in IgA Nephropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "BHV-1400",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-07-30",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 14,
      "location_summary": "Farmington, Connecticut • Miami Lakes, Florida • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07054684"
    },
    {
      "nct_id": "NCT06674577",
      "title": "A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy (IgAN)",
        "Renal and Urinary Disorders",
        "Berger Disease"
      ],
      "interventions": [
        {
          "name": "Atacicept 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 476,
      "start_date": "2024-12-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06674577"
    },
    {
      "nct_id": "NCT02384317",
      "title": "Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "CCX168",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2015-03-27",
      "completion_date": "2018-06-01",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • San Francisco, California • Reno, Nevada + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02384317"
    },
    {
      "nct_id": "NCT06989359",
      "title": "Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgAN",
        "C3G",
        "Complement-mediated Kidney Disease",
        "IgA Nephropathy (IgAN)",
        "IC-MPGN"
      ],
      "interventions": [
        {
          "name": "ADX-038 Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "ADX-038 Dose Level 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ADARx Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2025-08-28",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 11,
      "location_summary": "Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06989359"
    },
    {
      "nct_id": "NCT04042623",
      "title": "Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "AVB-S6-500",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aravive, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2019-11-27",
      "completion_date": "2020-08-01",
      "has_results": true,
      "last_update_posted_date": "2022-02-10",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 1,
      "location_summary": "Doral, Florida",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04042623"
    },
    {
      "nct_id": "NCT06712407",
      "title": "Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "TARPEYO®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-17",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06712407"
    },
    {
      "nct_id": "NCT05834738",
      "title": "Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy",
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "Atrasentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2023-07-20",
      "completion_date": "2025-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Oak Brook",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05834738"
    },
    {
      "nct_id": "NCT07020923",
      "title": "Monthly Dosing of Atacicept in IgAN",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy (IgAN)",
        "Berger Disease"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-05-29",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07020923"
    },
    {
      "nct_id": "NCT05003986",
      "title": "Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Immunoglobulin A Nephropathy",
        "IgA Vasculitis",
        "Alport Syndrome"
      ],
      "interventions": [
        {
          "name": "Sparsentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 67,
      "start_date": "2021-08-12",
      "completion_date": "2027-04-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-10T13:49:37.909Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05003986"
    }
  ]
}